⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2025

Table S2 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells

Soyoung Lee Kyunghwan Kim Hye‐Jin Jeong Subin Choi Himchan Cheng Dayoung Kim Soomin Heo Jinhee Mun Minjong Kim Eunjin Lee Yoon Ji Choi Seon‐gyeong Lee Eun A Lee Yewon Jang Kayeong Lim Heon Seok Kim Euihwan Jeong Seung‐Jae Myung Deok‐Beom Jung Chang Sik Yu In Ho Song M. Ryan Corces Joo H. Kang Kyungjae Myung Taejoon Kwon Tae‐Eun Park Jinmyoung Joo Seung Woo Cho

View Full Paper

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The combination of multiplexed CRISPR/Cas9-nickase and PARP inhibitors effectively targets cancer cells.
KEY EVIDENCE: The study provides detailed information on reagents used for culturing cancer organoids, enhancing precision.
APPROACH: The method employs a novel strategy using gene editing and drug inhibition to improve cancer treatment efficacy.
SIGNIFICANCE: This approach may lead to more efficient cancer therapies by precisely targeting cancerous tissues.
],

Implication

The technique combines multiplexed CRISPR with PARP inhibitors to enhance cancer organoid targeting, suggesting improved treatment strategies.

Abstract

Table S2 describes the information of the reagents used for the culture of cancer organoid.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d028d https://doi.org/10.1158/0008-5472.29760146

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
2Table S3 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
3Figure S15 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
4Figure S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025
5Table S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells2025